DE69737656T2 - Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung - Google Patents

Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung Download PDF

Info

Publication number
DE69737656T2
DE69737656T2 DE69737656T DE69737656T DE69737656T2 DE 69737656 T2 DE69737656 T2 DE 69737656T2 DE 69737656 T DE69737656 T DE 69737656T DE 69737656 T DE69737656 T DE 69737656T DE 69737656 T2 DE69737656 T2 DE 69737656T2
Authority
DE
Germany
Prior art keywords
cxcr3
antibody
protein
human
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737656T
Other languages
German (de)
English (en)
Other versions
DE69737656D1 (de
Inventor
Marcel Loetscher
Bernhard Moser
Shixin Lexington QIN
Charles R. Watertown MACKAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THEODOR KOCHER INSTITUT
Kocher Theodor Institut
Millennium Pharmaceuticals Inc
Original Assignee
THEODOR KOCHER INSTITUT
Kocher Theodor Institut
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27108320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69737656(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/709,838 external-priority patent/US6140064A/en
Application filed by THEODOR KOCHER INSTITUT, Kocher Theodor Institut, Millennium Pharmaceuticals Inc filed Critical THEODOR KOCHER INSTITUT
Application granted granted Critical
Publication of DE69737656D1 publication Critical patent/DE69737656D1/de
Publication of DE69737656T2 publication Critical patent/DE69737656T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69737656T 1996-09-10 1997-09-10 Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung Expired - Lifetime DE69737656T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US709838 1996-09-10
US08/709,838 US6140064A (en) 1996-09-10 1996-09-10 Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US08/829,839 US6184358B1 (en) 1996-09-10 1997-03-31 IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
US829839 1997-03-31
PCT/US1997/015915 WO1998011218A1 (en) 1996-09-10 1997-09-10 Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use

Publications (2)

Publication Number Publication Date
DE69737656D1 DE69737656D1 (de) 2007-06-06
DE69737656T2 true DE69737656T2 (de) 2008-01-03

Family

ID=27108320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737656T Expired - Lifetime DE69737656T2 (de) 1996-09-10 1997-09-10 Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung

Country Status (8)

Country Link
EP (1) EP0925358B1 (enExample)
JP (1) JP4502408B2 (enExample)
AT (1) ATE360689T1 (enExample)
AU (1) AU734090B2 (enExample)
CA (1) CA2265915C (enExample)
DE (1) DE69737656T2 (enExample)
ES (1) ES2288305T3 (enExample)
WO (1) WO1998011218A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6903194B1 (en) 1996-09-26 2005-06-07 Chungai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
SE9801098D0 (sv) * 1998-03-30 1998-03-30 Astra Pharma Prod Receptors
WO1999056532A1 (en) * 1998-05-07 1999-11-11 William Douglas Mckee Valve assembly
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response
EP1127126B1 (en) * 1998-11-06 2006-10-18 Bayer HealthCare AG G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
ATE342979T1 (de) 1999-08-03 2006-11-15 Millennium Pharm Inc 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
MXPA02005199A (es) * 1999-11-24 2002-11-07 Schering Corp Metodos para inhibir metastasis.
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
AU2001249546A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Methods for treating disease with antibodies to cxcr3
EP1987842A1 (en) 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitor
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
CA2452544A1 (en) * 2001-07-12 2003-01-23 The Regents Of The University Of California Method for treating secondary tissue degeneration associated with central nervous system injury
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2003072134A1 (fr) * 2002-02-28 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et therapeutiques pour la pneumonie interstitielle
US20050119174A1 (en) * 2002-04-03 2005-06-02 Sumitomo Pharmaceuticals Co. Ltd. Novel blood sugar controller and method of screening the same
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
DE60327106D1 (de) 2002-12-20 2009-05-20 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7405275B2 (en) 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
AU2005219322B2 (en) * 2004-03-09 2008-09-18 Kyoto University Pharmaceutical Composition Comprising CXCR3 Inhibitor
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2006116319A2 (en) 2005-04-21 2006-11-02 Chemocentryx, Inc. Reagents that bind ccx-ckr2
CA3009680C (en) * 2006-03-16 2023-08-15 Symthera Canada Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
JP5371780B2 (ja) * 2007-02-01 2013-12-18 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Ｃｘｃｒ３に対するヒト化抗体
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
ES2383568T3 (es) 2007-07-12 2012-06-22 Chemocentryx, Inc. Heteroaril piridil y fenil bencenosulfonamidas condensadas como moduladores de CCR2 para el tratamiento de la inflamación
PT2804878T (pt) * 2012-01-20 2018-11-29 Genzyme Corp Anticorpos anti-cxcr3
EP2866830A4 (en) * 2012-06-27 2015-12-09 Jyant Technologies ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION
US9681647B2 (en) 2012-07-05 2017-06-20 Cornell University Mammal with an orthotopic tumor capable of metastasis, a method of making and a method of using
WO2014186842A1 (en) * 2013-05-22 2014-11-27 Monash University Antibodies and uses thereof
IL266751B (en) 2016-11-23 2022-07-01 Chemocentryx Inc Method of treating focal segmental glomerulosclerosis
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN111417389A (zh) 2017-10-11 2020-07-14 坎莫森特里克斯公司 Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2022152767A2 (en) * 2021-01-12 2022-07-21 Charité - Universitätsmedizin Berlin A cxcr3+ cell or cell preparation for use in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486572B1 (en) * 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
EP0669979B1 (en) * 1992-11-10 2005-10-12 Genentech, Inc. C-c ckr-1, c-c chemokine receptor
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor

Also Published As

Publication number Publication date
ES2288305T3 (es) 2008-01-01
CA2265915C (en) 2012-11-20
ATE360689T1 (de) 2007-05-15
CA2265915A1 (en) 1998-03-19
JP2002513388A (ja) 2002-05-08
WO1998011218A1 (en) 1998-03-19
AU734090B2 (en) 2001-06-07
DE69737656D1 (de) 2007-06-06
JP4502408B2 (ja) 2010-07-14
AU4260897A (en) 1998-04-02
EP0925358A1 (en) 1999-06-30
EP0925358B1 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
DE69737656T2 (de) Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US6184358B1 (en) IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor
EP0932626B1 (en) G protein-coupled receptor antagonists
DE60130538T2 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
US6806061B1 (en) G protein-coupled receptor gene and methods of use therefor
US7858326B2 (en) Method of diagnosis of inflammatory disease using eotaxin antibodies
WO1996022371A9 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
AU2005202131B8 (en) CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
DE60203324T2 (de) Einzelne und duale anti-cd4-rantes chemokin/zytokin konstrukte
AU779916B2 (en) CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
AU3709601A (en) G protein-coupled receptor antagonists

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings